ATE355377T1 - Hybridprotease mit verringerter antigenizität und deren verwendung - Google Patents

Hybridprotease mit verringerter antigenizität und deren verwendung

Info

Publication number
ATE355377T1
ATE355377T1 AT01908667T AT01908667T ATE355377T1 AT E355377 T1 ATE355377 T1 AT E355377T1 AT 01908667 T AT01908667 T AT 01908667T AT 01908667 T AT01908667 T AT 01908667T AT E355377 T1 ATE355377 T1 AT E355377T1
Authority
AT
Austria
Prior art keywords
reduced antigenicity
hybrid protease
protease
hybrid
antigenicity
Prior art date
Application number
AT01908667T
Other languages
English (en)
Inventor
David A Estell
Fiona A Harding
Original Assignee
Genencor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int filed Critical Genencor Int
Application granted granted Critical
Publication of ATE355377T1 publication Critical patent/ATE355377T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
AT01908667T 2000-02-08 2001-01-22 Hybridprotease mit verringerter antigenizität und deren verwendung ATE355377T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/500,135 US6838269B1 (en) 1998-04-15 2000-02-08 Proteins producing an altered immunogenic response and methods of making and using the same

Publications (1)

Publication Number Publication Date
ATE355377T1 true ATE355377T1 (de) 2006-03-15

Family

ID=23988185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908667T ATE355377T1 (de) 2000-02-08 2001-01-22 Hybridprotease mit verringerter antigenizität und deren verwendung

Country Status (12)

Country Link
US (1) US6838269B1 (de)
EP (1) EP1254240B1 (de)
JP (1) JP5112587B2 (de)
KR (1) KR20020073582A (de)
CN (3) CN1721442A (de)
AR (1) AR027358A1 (de)
AT (1) ATE355377T1 (de)
AU (1) AU3651201A (de)
CA (1) CA2399019A1 (de)
DE (1) DE60126915T2 (de)
DK (1) DK1254240T3 (de)
WO (1) WO2001059130A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
JP2004532618A (ja) * 2001-02-06 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたレプチン
EP1461072A4 (de) * 2001-12-31 2005-02-09 Genencor Int Eine veränderte immunologische reaktion hervorrufende proteasen und herstellungs- und verwendungsverfahren dafür
EP2287321B1 (de) * 2002-01-16 2014-08-13 Danisco US Inc. Mehrfach substituierte Proteasevarianten
DE60331224D1 (de) * 2002-02-26 2010-03-25 Genencor Int Subtilisin-carlsberg-proteine mit verminderter immunogenität
US20060228791A1 (en) * 2002-06-26 2006-10-12 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
WO2004078960A1 (en) * 2003-02-26 2004-09-16 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (de) * 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
EP1863529A1 (de) * 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Neue zusammensetzung
EP1877087B1 (de) * 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
EP3327122B1 (de) 2014-07-04 2021-02-17 Novozymes A/S Subtilasevarianten und polynukleotide zur codierung davon
EP3739029A1 (de) 2014-07-04 2020-11-18 Novozymes A/S Subtilasevarianten und polynukleotide zur codierung davon
EP3464582A1 (de) * 2016-06-03 2019-04-10 Novozymes A/S Subtilasevarianten und polynukleotide zur codierung davon

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482133A1 (es) 1978-07-04 1980-04-01 Novo Industri As Un procedimiento para preparar un concentrado de proteasa.
US5700676A (en) * 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
KR100237968B1 (ko) 1990-12-05 2000-01-15 한센 핀 베네드 변화된 에피토프를 지닌 단백질 및 그 제조방법
US5593877A (en) * 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
JPH10509324A (ja) 1994-11-24 1998-09-14 ノボ ノルディスク アクティーゼルスカブ 抑制されたアレルゲン性を有するポリペプチドの製造のための方法
US5951980A (en) * 1995-01-06 1999-09-14 Leuven Research & Development Vzw Identification, production and use of new staphylokinase derivatives with reduced immunogenicity
CA2219949C (en) 1995-05-05 2013-09-24 Novo Nordisk A/S Protease variants and compositions
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
JP2000506119A (ja) 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
CA2270180C (en) 1996-11-04 2011-01-11 Novo Nordisk A/S Subtilase variants and compositions
EP1724282B1 (de) 1997-05-21 2013-05-15 Merck Patent GmbH Verfahren zur Herstellung von nicht-immunogenen Proteinen
WO1999006061A1 (en) 1997-07-29 1999-02-11 The Administrators Of The Tulane Educational Fund Prediction, detection, and design of t cell epitopes
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CA2238660A1 (en) 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.

Also Published As

Publication number Publication date
DE60126915D1 (de) 2007-04-12
JP5112587B2 (ja) 2013-01-09
JP2004500088A (ja) 2004-01-08
KR20020073582A (ko) 2002-09-27
WO2001059130A2 (en) 2001-08-16
CA2399019A1 (en) 2001-08-16
AU3651201A (en) 2001-08-20
US6838269B1 (en) 2005-01-04
AR027358A1 (es) 2003-03-26
WO2001059130A3 (en) 2002-03-07
CN1721442A (zh) 2006-01-18
EP1254240A2 (de) 2002-11-06
CN101906464A (zh) 2010-12-08
DK1254240T3 (da) 2007-07-02
EP1254240B1 (de) 2007-02-28
CN101906464B (zh) 2013-03-27
DE60126915T2 (de) 2007-11-15
CN1418253A (zh) 2003-05-14

Similar Documents

Publication Publication Date Title
ATE355377T1 (de) Hybridprotease mit verringerter antigenizität und deren verwendung
DE60143666D1 (de) Flachbatterie und herstellungsverfahren dafür
DE60135100D1 (de) E mit ultradünnem elektrolyten
DE60310762D1 (de) Halbleiterbauelement mit reduzierten defekten in einer aktiven region und kontaktschema
ATE402191T1 (de) Rekombinante il-18 antikörper und deren verwendung
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
BR0110864B1 (pt) artigo absorvente com lados passìveis de serem fechados novamente.
DE60141406D1 (de) Hosenähnlicher absorbierender artikel mit gekrümmten beinabschlüssen
PT1157023E (pt) Epotilonas modificadas em c-21
DE60022707D1 (de) Hilfskraft- und Hilfsschubantrieb
PT1043239E (pt) Recipiente com lados colapsaveis
DE60105859D1 (de) Urazil Verbindungen und deren Verwendung
DE60115114D1 (de) Graphitnanofaser und deren Verwendung
DK1122806T3 (da) Fastoxid brændselscelle
DE50106237D1 (de) Querträger in Hybridbauweise
DE60235715D1 (de) Absorbierender artikel mit selbstformenden abdichtungen
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60136122D1 (de) Brennstoffzelle und Brennstoffzellenanlage
DE60120092D1 (de) Thermoplastische elastomerzusammensetzung mit grosser thermischer stabilität
DE60141669D1 (de) Sekundärzellen mit Polabdichtungsstruktur
DE60111709D1 (de) Reifen mit genau angeordneten und orientierten Elementen
DE60216345D1 (de) Gummimischung und deren Verwendung
DE50115716D1 (de) Tetrakisfluoroalkylborat-Salze und deren Verwendung als Leitsalze
DE60142405D1 (de) Multi-axiale lastzelle
FI20010557A0 (fi) Menetelmä vaihtosuuntaajan yhteydessä

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties